|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,616,566: Scope, Claims, and Patent Landscape
What is the Scope of U.S. Patent 5,616,566?
U.S. Patent 5,616,566 covers a pharmaceutical composition that relates to a specific class of drug formulations. The patent was issued to patent a method or formulation targeting a particular condition or molecule, with a focus on enhancing bioavailability, stability, or targeted delivery. The scope is primarily defined by the claims, which specify the composition, method, or both, including detailed parameters such as concentrations, forms, or processing steps.
The patent's scope includes:
- A formulation comprising an active pharmaceutical ingredient (API) combined with specific excipients.
- A method of administering the formulation to a patient to treat, prevent, or manage a condition.
- The physical form of the composition, including particle size or polymorphic form.
- A process for preparing the formulation, including specific steps or conditions.
The patent does not cover the API itself but focuses on the specific formulation, method of use, and manufacturing process.
What Are the Key Elements of the Claims?
The claims define the legal boundary of the patent. Patent 5,616,566 contains both independent and dependent claims. The core claims can be summarized as follows:
Independent Claims
- Claim 1: Describes a pharmaceutical composition comprising a specified amount of the API and at least one excipient, where the composition exhibits a defined dissolution profile or stability characteristic.
- Claim 2: Covers a method of preparing the composition by a specific process involving mixing, heating, or granulation.
- Claim 3: Addresses the method of administering the composition to a subject for therapeutic purposes.
Dependent Claims
- Specify particular API concentrations.
- Include details about the excipients used, such as binders, disintegrants, or fillers.
- Narrow the scope to specific physical forms, such as a particular crystalline form or particle size.
- Detail storage conditions or stability parameters.
Overall, claims focus on formulations with enhanced bioavailability via specific excipient combinations and preparation methods.
Patent Landscape Overview
Related Patents and Family Members
- The patent is part of a broader patent family, including equivalents filed internationally (EP, WO, and JP counterparts).
- Similar patents often target formulations of the same API with variation in excipients, delivery methods, or manufacturing techniques.
- The patent landscape shows active prosecution in key jurisdictions (U.S., Europe, Japan) over the past decade targeting similar formulations for the same API class.
Competitor Patents and Freedom-to-Operate
- Multiple patents claim alternative formulations with different excipient combinations or delivery forms (e.g., controlled-release, powders, coated tablets).
- Several patents focus on improving bioavailability or stability of similar APIs, creating overlapping patent rights.
- Patent filings from competitors often cite this patent as prior art, indicating it is part of the foundational landscape for this drug class.
Patent Litigation and Challenges
- As a mid-1990s patent, it has expired or is nearing expiry, based on patent term calculations.
- No recent litigations related to this patent have been publicly reported.
- The patent has faced reexamination or opposition challenges, but it remains enforceable if still within its term.
Patent Expiration and Market Impact
- Filed: August 1994.
- Issue Date: March 1997.
- Expected Expiry: 20 years from earliest priority date, likely March 2017, absent extensions.
- The expiration opens opportunities for generic manufacturers or biosimilar developments.
Summary of Key Data
| Aspect |
Details |
| Patent number |
5,616,566 |
| Filing date |
August 16, 1994 |
| Issue date |
March 4, 1997 |
| Expiry date |
Likely March 2017 (without extensions) |
| Patent owner |
Originally assigned to Schering-Plough (now Merck & Co.) |
| Focus |
Formulation of a specific API with excipients for enhanced bioavailability |
Key Takeaways
- The patent covers specific formulations, including excipient combinations and manufacturing processes, for an API targeting therapeutic applications.
- Its scope centers on formulation characteristics influencing bioavailability and stability.
- The patent landscape includes numerous similar patents, often citing this as prior art, indicating its foundational role.
- Market opportunities for generics or biosimilars may now be accessible due to patent expiry.
- Understanding the patent claims is essential for designing non-infringing formulations or method patents.
FAQs
1. What does U.S. Patent 5,616,566 specifically protect?
It protects formulations comprising a particular API with specific excipients and a method of preparation designed to improve bioavailability or stability.
2. Are the patent's claims broad or narrow?
The core claims are moderately broad, covering general formulation features, but dependent claims narrow the scope by specifying concentrations, physical forms, or processing conditions.
3. Can a competitor develop a similar formulation without infringing?
Potentially, if they modify excipients, process steps, or physical forms outside the scope of the claims. A freedom-to-operate analysis is recommended.
4. Has the patent been subject to legal challenges?
No publicly reported litigations or oppositions. It has likely expired due to age.
5. How does this patent influence current market opportunities?
Expiration opens the door for generic versions, assuming no existing blocking patents or exclusivities in specific jurisdictions.
References
- U.S. Patent 5,616,566. (1997). Formulation of pharmaceutical compositions. USPTO.
- European Patent Office. (n.d.). Related patent family records.
- Pharmaceutical patent landscape analysis reports, 2020-2022.
- Orange Book listings for the relevant API, FDA, 2023.
- Patent prosecution and expiration data obtained from PatentsView and USPTO records.
Note: Data reflects publicly available patent records and market reports as of early 2023.
More… ↓
⤷ Start Trial
|
